PD-L1 TPS ≥1%
1 drugsPredictive biomarker for patient selection in 25 indications
1
Approved Drugs
25
Indications
1
Companies
PD-L1 TPS ≥1% is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 25 indications including Melanoma, Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma. Explore the targeted therapies, indications, testing methods, and companies developing PD-L1 TPS ≥1% drugs below.
Search PD-L1 TPS ≥1% Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting PD-L1 TPS ≥1%
| Drug | Company | Therapeutic Area |
|---|---|---|
| KEYTRUDA | Merck | Oncology |
PD-L1 TPS ≥1% Indications
Melanoma Non-Small Cell Lung Cancer Malignant Pleural Mesothelioma Head and Neck Squamous Cell Cancer Classical Hodgkin Lymphoma Primary Mediastinal Large B-Cell Lymphoma Urothelial Cancer Microsatellite Instability-High Cancer Mismatch Repair Deficient Cancer Colorectal Cancer Gastric Cancer Gastroesophageal Junction Adenocarcinoma Esophageal Cancer Cervical Cancer Hepatocellular Carcinoma Biliary Tract Cancer Merkel Cell Carcinoma Renal Cell Carcinoma Endometrial Carcinoma Tumor Mutational Burden-High Cancer Cutaneous Squamous Cell Carcinoma Triple-Negative Breast Cancer Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer